BioPharmSignal logoBioPharmSignal

Biotech News

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

Biodesix (BDSX)BiodesixEarnings

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2026 after the close of trading on Thursday, November 5. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

Related news

BDSXBiodesix2026-07-22 10:00 EST

Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026

BDSXBiodesix2026-04-20 10:00 EST

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

SERASera Prognostics2026-10-21 20:05 EST

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON NOVEMBER 4, 2026

FLGTFulgent Genetics, Inc.2026-10-15 20:05 EST

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

DGXQuest Diagnostics2026-10-22 10:46 EST

Quest Diagnostics Reports Third Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

DGXQuest Diagnostics2026-09-22 20:28 EST

Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026

LUCDLucid Diagnostics2026-08-13 12:00 EST

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

SERASera Prognostics2026-08-12 20:05 EST

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

OSUROraSure Technologies, Inc.2026-08-05 20:05 EST

OraSure Announces Second Quarter 2026 Financial Results

BRLIBio-Reference Laboratories2026-07-27 20:05 EST

OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results

View all latest news

Biodesix

Lung-Disease Diagnostics Biodesix develops and commercializes diagnostic solutions intended to improve clinical decision-making, with a particular focus on lung disease and oncology. Its tests combine multiple analytical technologies with clinical evidence and laboratory operations. Diagnostic Testing The company provides blood-based and...

Recent company news

BDSXBiodesix2026-10-22 10:00 EST

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

BDSXBiodesix2026-10-19 20:01 EST

American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

BDSXBiodesix2026-10-19 10:00 EST

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

BDSXBiodesix2026-10-13 10:00 EST

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

BDSXBiodesix2026-09-24 10:00 EST

Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Stock data

Close
23.94 USD
Market cap
159.89M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States